EAM Investors’s Cue Biopharma CUE Stock Holding History

EAM Investors’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,544	Closed	-$1.14M	–	297
2020 Q2	$1.14M	Buy	+1,544	New	+$1.12M	0.25%	181

Other funds holding CUE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

EAM Investors's CUE Position: Q3 2020 in Review

EAM Investors sold out of Cue Biopharma (CUE) in Q3 2020, closing a stake of 1,544 shares — an estimated $1.14M sold.

EAM Investors first reported a position in CUE in Q2 2020 and held it in 1 quarter. The position peaked at $1.14M in Q2 2020. 92 funds tracked by Wall St. Rank hold CUE as of Q3 2020.

EAM Investors reported no remaining Cue Biopharma position as of Q3 2020 after selling out during the quarter.
EAM Investors sold 1,544 Cue Biopharma shares in Q3 2020, an estimated $1.14M.
EAM Investors first reported a position in Cue Biopharma in Q2 2020 and held it in 1 quarter.
EAM Investors's Cue Biopharma position peaked at $1.14M in Q2 2020.
92 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2020.

Based on EAM Investors's 13F filing for Q3 2020, filed 13 Nov 2020.